ARTICLE | Clinical News

Jetrea ocriplasmin regulatory update

January 6, 2014 8:00 AM UTC

On Dec. 27, 2013, ThromboGenics said the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended reimbursing Jetrea ocriplasmin from ThromboGenics to treat symptomatic vitreomacular adhesion (VMA), a precursor to vitreomacular traction (VMT). The CADTH makes recommendations to provincial and other drug plans through the Common Drug Review. All provinces except Quebec participate in the review. ...